IL17A and systemic sclerosis: Despite many evidences appear to confirm the involvement of IL-17 in physio-pathological processes in SSc, its exact role in this disease remains uncertain and the clinical implications of the altered IL-17 profile are still controversial, even if IL-17 could represent an intriguing potential therapeutic target.